Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 2, 2019Alimentary Pharmacology & TherapeuticsOpen Access

Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside

View Full Paper
Ask AI
Bookmark
Share

Authors

TDTrond Espen DetlieJLJonas Christoffer LindstrømMJMarte Eide Jahnsen

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Detlie et al. (2019) studied this question.

synapsesocial.com/papers/6aa92ea29965218ad462e07dhttps://doi.org/10.1111/apt.15386
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rapid Recurrence of IBD-Associated Anemia and Iron Deficiency After Intravenous Iron Sucrose and Erythropoietin Treatment2009 · 116 citations
  2. 2The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency2017 · 25 citations
  3. 3Screening, Diagnosis and Treatment of Iron Deficiency in Chronic Heart Failure: Putting the 2016 European Society of Cardiology Heart Failure Guidelines Into Clinical Practice2018 · 120 citations